Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-06-12
2007-06-12
Wehbe′, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S023700
Reexamination Certificate
active
10088569
ABSTRACT:
Nucleic acid, including DNA, immunization is used to generate a protective immune response in a host, including humans, to a serine-threonine kinase (STK) of a strain ofChlamydia. A non-replicating vector, including a plasmid vector, contains a nucleotide sequence encoding a STK or a fragment of the STK that generates antibodies that specifically react with STK and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the STK in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.
REFERENCES:
patent: 5589466 (1996-12-01), Felgner et al.
patent: 6001372 (1999-12-01), DeMars et al.
patent: 0192033 (1986-08-01), None
patent: WO 98/02546 (1998-01-01), None
Alberts et al. (1994, Molecular Biology of the Cell, Third Edition, Garland Publishing: New York, p. 1195).
NCBI nucleotide printout,Chlamydia trachomatisD/UW-3/Cs section 15 of 87 of the complete genome, gi No.: 3328545.
Read et al. 2000, Nucleic Acid Research 28: 1397-1406.
Stephens RS et al. 1998, Science, 282: 754-759.
Chattergoon et al. 1997, The FASEB Journal, 11: 753-763.
Ulmer, 2001, Curr. Opin. Drug Discov. Devel. 4: 192-7. see abstract.
Cui, 2005, Adv. Genet. 54: 257-289, see abstract.
Proceedings of the Chlamydia Vaccine Development Colloquium, Jun. 4-5, 2003, edited by Woodall, J.P., The Albert B. Savin Vaccine Institute, 1st edition.
Somia and Verma, 2000, Nature Reviews: Genetics, 1: 91-99.
Minchin et al., 2001, J. of Pharm. and Exp. Therap., 296: 1006-1012.
Donnelly et al, Protective efficacy of intramuscular immunization with naked DNA. vol. 772 40-46 (1995).
D. M. Pardoll and A. M. Beckerieg, Exposing the immunology of naked DNA vaccines. vol. 3, 165-169 (1995).
W.M. McDonnell and F. K. Askari, Molecular Medicine. DNA vaccines. vol. 334, 42-45 (1996).
J. B. Ulmer et al., Heterologous protection against influenza by injection of DNA encoding a viral protein. vol. 259, 1745-1749 (1993).
B. Wang et al., Gene inoculation generates immune responses against human immunodeficiency virus type 1. vol. 90, 4156-4160 (1993).
G. J. M. Cox, et al., Bovine Herpesvirus 1: Immune responses in mice and cattle injected with plasmid DNA. vol. 67, 5664-5667 (1993).
E. Raz et al., Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. vol. 91, 9519-9523 (1994).
Z. Q. Xiang et al., Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. 199, 132-140 (1994).
J.J. Donnelly et al., Protection against papillomavirus with a polynucleotide vaccine. vol. 713, 314-320 (1996).
D. L. Montgomery et al., Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors. vol. 12, 777-783 (1993).
J.J. Donnelly et al., Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. vol. 1, 583-587 (1995).
G. H. Rhodes et al., Characterization of humoral immunity after DNA injection. vol. 82, 229-236 (1994).
H. L. Davis, M. L. Michel, R. G. Whalen, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. vol. 2, 1847-1851 (1993).
J. B. Ulmer. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. vol. 12, 154 1-1544 (1994).
Z. Xiang and H. C. J. Ertl. Manipulation of the immune response to a plasmid-encoded viral antigen by coinculation with plasmids expressing cytokines. vol. 2, 129-135 (1995).
E. F. Fynan et al, DNA vaccines: Protective immunization by parenteral, mucosal, and gene-gun inoculations, vol. 90, pp. 11478-11482 (1993).
E. Manickan, et al., Genetic immunization against herpes simplex virus. vol. 155, 259-265 (1995).
M. Sedegah et al , Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. vol. 91, pp. 9866-9870 (1994).
M.A. Barry, et al., Protection against mycoplasma infection using expression-library immunization. vol. 377, 632-635 (1995).
D. Xu and F. Y. Liew, Genetic vaccination against leishmaniasis. vol. 12, 1534-1536 (1994).
D. B. Lowrie, et al., Towards and DNA vaccine against tuberculosis. vol. 12, 1537-1540 (1994).
J. W. Moulder, et al., Interaction of chlamydiae and host cells in vitro. vol. 55, 143-190 (1991).
J. Schachter, The intracellular life of chlamydia. vol. 138, 109-139 (1988).
S. D. Hillis and J. N. Wasserheit, Screening for chlamydia-a key to the prevention of pelvic inflammatory disease. vol. 334, 1399-1401 (1996).
R. C. Brunham and R. W. Peeling,Chlamydia trachomatisantigens: Role in immunity and pathogenesis. vol. 3, 218-233 (1994).
R. P. Morrison, D.S. Manning, H. D. Caldwell, Immunology ofchlamydial trachomatisinfections. 1992, pp. 57-84.
J. T. Grayston and S-P. Wang, The potential for vaccine against infection of the genital tract withchlamydia trachomatis. vol. 5, 73-77 (1978).
J. T. Grayston and S.-P Wang, New knowledge of chlamydia and the diseases they cause. vol. 132, 87-105 (1975).
H. R. Taylor, et al. Oral immunization with chalmydia major route membrane protein (MOMP) vol. 29, 1847-1853 (1988).
B.E. Batteiger, et al., Partial protection against genital reinfection by imunization of guinea pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjuctivitis. 139, pp. 2965-2972 (1993).
M. Campos et al., A chlamydial major outer membrane protein extract as trachoma vaccine candidate. vol. 36, 1477-1491 (1995).
H. Su, M. Parnell, et al., Protective efficacy of parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model ofChlamydia trachomatisgential tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. vol. 13, 1023-1032 (1995).
T.-W. Tan, Protection of sheep againstchlamudia psittaciinfection with a subcellular vaccine containing the major outer membrane protein. vol. 58, 3101-3108 (1990).
M. Tuffrey, et al., Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate ofChlamudia trachomatisby prior immunization with recombinant serovar L1 major outer-membrane protein. 138, 1707-1715 (1992).
Y.-X. Zhang, J. G. Fox, Y. Ho., Comparsion of the major Outer-Membrane protein (MOMP) gene of mouse pneumonitis (MoPn) and hamster SFPD strans ofchlamydia trachomatiswith other Chlamydia strains. 10(6), pp. 1327-1342 (1993).
R. P. Morrison, et al., Gene knockout mice establish a primary protective role for major histocompatibility complex class II-Restricted responses inchlamydia trachomatisgenital tract infection, vol. 63, 4661-4668 (1995).
H. Su and H. D. Caldwell, CD4+T cell play a singnificant role in aadoptive immunity tochlamydia trachomatisinfection of the mouse genital tract. vol. 63, 3302-3308 (1995).
J. U. Igietseme et al., Resolution of murine chlamydial genital infection by the adoptive transfer of Biovar-Specific, TH1 Lymphocyte Clone. 5, 317-324 (1993).
J. U. Igietseme, et al., Susceptibility to reinfection after a primary chlamydia genital infection is associated with a decrease of antigen-specific T cells in the genital tract. vol. 59, 1346-1351 (1991).
D. M. Williams, et al., Cellular immunity to the mouse pneumonitis agent. vol. 149, 630-639 (1984).
G. Tipples and G. McClarty, Cloning and expression of thechlamydia trachomatisgene for CTP synthetase. vol. 270, 7908-7914 (1995).
X. Yang, K. et al., Genetically determined differences in IL-10 and IFN-v response correlate with clearance of chlanydia trachomatid mouse pneumonitis inflection. vol. 156, 4338-4344 (1996).
Tang et al., Genetic immunization is a simple method for eliciting an immune response. 1992, vol. 356, pp. 152-154.
Davis et al., Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. 1994, vol. 12: 1503-1509.
Holzman L.B. et al., Identification, molecualr cloning, and characterzation of dula leucine z
Hama Joanne
Sim & McBurney
Stewart Michael I.
University of Manitoba
Wehbe′ Anne M.
LandOfFree
DNA immunization against chlamydia infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA immunization against chlamydia infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA immunization against chlamydia infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3863251